PANACEABIO - Panacea Biotec
📢 Recent Corporate Announcements
Panacea Biotec's wholly-owned subsidiary, Panacea Biotec Pharma Limited (PBPL), has received a favorable order from the Deputy Commissioner of State Tax, Maharashtra. The tax authority reduced a previous demand of ₹1.58 Crore to ₹0.81 Crore, which includes tax, interest, and penalties related to alleged ineligible Input Tax Credit from FY 2024-25. Despite the reduction, the company maintains that the remaining demand is not maintainable and plans to file a further appeal. The company has stated that this development will not have a material impact on its financial or operational activities.
- Tax demand reduced from ₹1.58 Crore to ₹0.81 Crore by Maharashtra tax authorities
- Litigation involves alleged excess or ineligible Input Tax Credit (ITC) and other tax liabilities
- Subsidiary PBPL intends to file an appeal against the revised ₹0.81 Crore order
- Management confirms no significant impact on financial, operation, or other activities
Panacea Biotec has received a favorable ruling from the Income Tax Appellate Tribunal (ITAT) regarding long-standing tax disputes for Assessment Years 2005-06 to 2012-13. The ITAT dismissed eight appeals by the tax department and allowed two appeals by the company, effectively quashing the previous assessment orders. This decision results in the cancellation of a massive tax demand totaling ₹329.49 Crore. The ruling removes a significant contingent liability and potential penalty exposure from the company's financial records.
- ITAT quashed assessment orders for eight Assessment Years spanning 2005-06 to 2012-13.
- Cancellation of a total tax demand amounting to ₹329.49 Crore previously raised by the Assessing Officer.
- Deletion of all expense disallowances that were under litigation since Financial Year 2015-16.
- The ruling dismisses eight appeals filed by the Deputy Commissioner of Income Tax (DCIT) against the company.
Panacea Biotec reported a consolidated net profit of ₹389 lakh for the quarter ended December 31, 2025, a slight decline from ₹444 lakh in the previous year. Consolidated revenue from operations grew marginally to ₹16,519 lakh compared to ₹16,349 lakh YoY. However, the standalone business faced significant pressure, reporting a net loss of ₹736 lakh against a profit of ₹965 lakh in the same period last year. The company continues to benefit from exceptional income, including a ₹858 lakh settlement with Apotex Inc. and deferred consideration from previous brand sales.
- Consolidated revenue from operations increased 1.04% YoY to ₹16,519 lakh.
- Formulations segment EBIT turned positive at ₹906 lakh compared to a loss of ₹758 lakh in Q3 FY25.
- Vaccines segment reported a loss of ₹257 lakh at the EBIT level for the quarter.
- Exceptional income of ₹1,679 lakh recognized in 9M FY26, including ₹858 lakh from a settlement with Apotex Inc.
- Standalone net loss for 9M FY26 widened significantly to ₹2,970 lakh from ₹284 lakh in 9M FY25.
Panacea Biotec reported a consolidated net profit of ₹3.89 crore for Q3 FY26, a slight decline from ₹4.44 crore in the same quarter last year. Consolidated revenue from operations grew marginally by 1% YoY to ₹165.19 crore. For the nine-month period, the company remains in a net loss of ₹6.16 crore, though this narrowed from a loss of ₹6.73 crore in the previous year. The results were significantly supported by an exceptional income of ₹16.79 crore in the 9M period, including a settlement with Apotex Inc.
- Consolidated Q3 revenue reached ₹165.19 crore, a marginal 1% increase over the previous year's ₹163.49 crore.
- Formulations segment profit improved significantly to ₹9.06 crore from a loss of ₹7.58 crore in Q3 FY25.
- Vaccines segment reported a loss of ₹2.57 crore for the quarter despite revenue of ₹99.24 crore.
- Exceptional income of ₹16.79 crore for 9M FY26 includes ₹8.58 crore from a settlement with Apotex Inc.
- Standalone net loss stood at ₹7.36 crore for Q3 FY26, compared to a profit of ₹9.65 crore in Q3 FY25.
Panacea Biotec Limited has filed its monthly update regarding the dematerialization of securities for January 2026 as per SEBI regulations. The company confirmed that no shares were dematerialized during the month. As of January 31, 2026, the total number of dematerialized shares remains at 6,11,01,526. The majority of these shares are held with NSDL, accounting for over 5.34 crore shares.
- Zero shares were dematerialized during the month of January 2026
- Total dematerialized shares as of January 31, 2026, stand at 6,11,01,526
- NSDL holds 5,34,32,223 dematerialized shares
- CDSL holds 76,69,303 dematerialized shares
Panacea Biotec's subsidiary facility in Baddi has received a 'Statement of non-compliance' with Good Manufacturing Practices (GMP) from Hungary's NCPHP, resulting in the revocation of its GMP certificates. The regulator has proposed halting supplies of non-vital products to the EU market, though no quality risks were found in products already released. The financial impact is expected to be minimal as the EU market contributed only 0.32% of the company's total consolidated net revenues in FY 2024-25. The company is currently implementing corrective and preventive actions (CAPA) to seek a re-inspection and restore compliance.
- NCPHP Hungary issued a Statement of non-compliance with GMP for the Baddi facility on February 03, 2026.
- All valid GMP certificates issued by NCPHP for the facility have been revoked following the inspection.
- Revenue from the European Union market accounted for only 0.32% of consolidated net revenues in FY 2024-25.
- No quality risks were observed by regulators for products already released into the market.
- Company is implementing CAPA and will request a re-inspection at the earliest to restore certificates.
Panacea Biotec has achieved a major milestone by completing the enrollment of 10,335 participants for the Phase III clinical trials of DengiAll, India's first indigenous single-shot dengue vaccine. The trial, conducted in collaboration with ICMR, will now move into a two-year monitoring phase to evaluate the vaccine's efficacy and immunogenicity. This development keeps the company on track for a projected market entry by 2027. Successful commercialization would address a significant unmet medical need in tropical regions, potentially creating a substantial long-term revenue stream.
- Completed enrollment of 10,335 study participants for Phase III clinical trials of DengiAll vaccine.
- DengiAll is positioned as India's first indigenous single-shot tetravalent dengue vaccine candidate.
- Two-year monitoring period initiated to examine long-term efficacy and immunogenicity post-administration.
- Commercial market launch is anticipated by 2027 following the completion of the observation period.
- Project is being executed in collaboration with the Indian Council of Medical Research (ICMR).
Panacea Biotec Limited has filed its compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025. The document confirms that physical share certificates received for dematerialization were verified, cancelled, and the depository's name was updated in the records. This process was completed within the mandatory 15-day window as certified by the Registrar and Transfer Agent, Skyline Financial Services. Such filings are standard regulatory requirements for listed entities to ensure the integrity of the shareholding system.
- Quarterly compliance certificate for the period ending December 31, 2025
- Dematerialization of physical shares processed within the 15-day regulatory timeline
- Registrar Skyline Financial Services confirmed the mutilation and cancellation of physical certificates
- Securities involved are listed on both NSE and BSE
Panacea Biotec Limited has submitted its monthly update regarding the dematerialization of shares for December 2025. During the month, a net total of 1,000 shares were dematerialized, bringing the total dematerialized share count to 6,11,01,526. The breakdown shows 5,32,20,273 shares held in NSDL and 78,81,253 shares in CDSL. This filing is a standard regulatory requirement under SEBI (Depositories and Participants) Regulations, 2018.
- Total dematerialized shares reached 6,11,01,526 as of December 31, 2025.
- A net increase of 1,000 shares in dematerialized form was recorded during December 2025.
- NSDL holdings stood at 5,32,20,273 shares, while CDSL holdings were 78,81,253 shares.
- The update was filed in compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
Panacea Biotec Limited has received three demand orders from the Income Tax Department totaling ₹9.38 Crore. The penalties are attributed to alleged under-reporting of income for Assessment Years 2017-18, 2020-21, and 2021-22. The company has declared the demand as not maintainable and intends to file an appeal with the appellate authority. While the company does not foresee an immediate operational impact, the final resolution of this litigation will determine the actual financial outflow.
- Aggregate penalty demand of ₹9.38 Crore received from the Assistant Commissioner of Income Tax, Delhi.
- Specific demands include ₹5.55 Crore for AY 2017-18, ₹3.11 Crore for AY 2020-21, and ₹0.72 Crore for AY 2021-22.
- Penalties imposed under Section 270A of the Income Tax Act, 1961 for alleged under-reporting of income.
- Company plans to contest the orders by filing an appeal with the relevant appellate authority.
Panacea Biotec Limited has announced the closure of its trading window for all designated persons starting January 1, 2026. This routine regulatory measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The closure is ahead of the announcement of the company's unaudited financial results for the quarter and nine months ending December 31, 2025. The trading window will remain closed until 48 hours after the financial results are officially declared to the stock exchanges.
- Trading window closure effective from January 1, 2026.
- Applies to all Designated Persons and their immediate relatives as per SEBI regulations.
- Closure is related to the financial results for the period ending December 31, 2025.
- Window to reopen 48 hours after the announcement of the unaudited financial results.
- The specific date for the Board Meeting to approve results will be notified separately.
Panacea Biotec has received an amendment to its existing contract with UNICEF for the supply of its WHO pre-qualified Pentavalent vaccine, Easyfive-TT®. The total value of the award has been increased by approximately $8.93 million (around ₹80 Crore) for the years 2026 and 2027. Specifically, the 2026 allocation increased by $2.55 million, while the 2027 allocation saw a combined increase and additional award totaling $6.38 million. This development strengthens the company's long-term revenue visibility and reinforces its partnership with international health organizations.
- Total contract value increased by $8.93 million (~₹80 Crore) for CY2026 and CY2027
- 2026 supply value increased by $2.55 million to a total of $16.8 million
- 2027 supply value increased by $6.38 million through amendments and additional awards
- Supplies involve the WHO pre-qualified fully liquid Pentavalent vaccine, Easyfive-TT®
- The contract is with an international entity (UNICEF), ensuring high credit quality
Panacea Biotec has announced key management changes. Mr. Vinod Goel, currently Group CFO, is appointed as CFO effective December 16, 2025, succeeding Mr. Devender Gupta. Consequently, Mr. Goel will cease to be the Company Secretary. Mr. Ankit Jain is appointed as Company Secretary and Compliance Officer from December 16, 2025. The board also adopted a revised policy for determining the Materiality of Events.
- Mr. Vinod Goel appointed as Group Chief Financial Officer and Head Legal & Corporate Governance w.e.f. December 16, 2025.
- Mr. Ankit Jain appointed as General Manager – Legal & Company Secretary w.e.f. December 16, 2025.
- Mr. Vinod Goel has over 35 years of post-qualification experience.
- Mr. Ankit Jain has around 15 years of experience in corporate governance and regulatory compliance.
- Revised Policy for determining Materiality of Events / Information effective December 16, 2025.
Panacea Biotec Limited announced the appointment of Mr. Ankit Jain as the Company Secretary & Compliance Officer, effective December 16, 2025. This follows the cessation of Mr. Vinod Goel from the role of Company Secretary and Compliance Officer on December 15, 2025, due to his appointment as Group CFO. Mr. Jain, aged about 38 years, previously served as Assistant General Manager - Legal of the company’s wholly owned subsidiary, Panacea Biotec Pharma Ltd. The board also revised the policy for determining materiality of events and authorized key managerial personnel for disclosures.
- Ankit Jain appointed as Company Secretary & Compliance Officer w.e.f. December 16, 2025
- Vinod Goel appointed as Group CFO and Head Legal & Corporate Governance w.e.f. December 16, 2025
- Vinod Goel ceases to be Company Secretary and Compliance Officer w.e.f. December 15, 2025
- Ankit Jain has around 15 years of experience in corporate governance
- Board meeting concluded at 03:36 P.M. on December 15, 2025
Panacea Biotec has appointed Mr. Vinod Goel as the Chief Financial Officer (CFO) with effect from December 16, 2025. Mr. Goel, who is currently the Group CFO and Head Legal & Company Secretary, will now be designated as Group Chief Financial Officer and Head Legal & Corporate Governance. This follows the resignation of Mr. Devender Gupta from the CFO position, effective December 15, 2025. Mr. Ankit Jain has been appointed as Company Secretary and Compliance Officer with effect from December 16, 2025.
- Mr. Vinod Goel appointed as CFO w.e.f. December 16, 2025
- Mr. Ankit Jain appointed as Company Secretary w.e.f. December 16, 2025
- Mr. Vinod Goel has over 35 years of post-qualification experience
- Mr. Ankit Jain has around 15 years of experience
Financial Performance
Revenue Growth by Segment
Consolidated revenue grew 15% YoY to INR 624.8 Cr in FY21. The Vaccine segment grew 62% YoY to INR 227.8 Cr, while the Pharmaceutical segment declined 2% YoY to INR 397.0 Cr. In H1 FY26, Vaccine revenue reached INR 203.06 Cr (up 52% from INR 133.49 Cr) and Formulations reached INR 104.77 Cr (down 19% from INR 129.58 Cr).
Geographic Revenue Split
Export revenue from pharmaceutical products was INR 183.83 Cr (74% of pharma revenue), growing 11% YoY. Domestic pharmaceutical revenue was INR 65.42 Cr (26% of pharma revenue), which surged 92% YoY primarily due to increased contract manufacturing activities.
Profitability Margins
Gross and operating margins were impacted by segment shifts; the Pharmaceutical business earned an EBITDA of INR 69.0 Cr in FY21 (down from INR 90.9 Cr), while the Vaccine business turned around from an EBITDA loss of INR 13.7 Cr to a profit of INR 11.3 Cr.
EBITDA Margin
Consolidated EBITDA margin was 12.8% in FY21, representing a decline from 14.2% in FY20. This was driven by lower pharmaceutical sales during the pandemic and a shift in the product mix toward vaccines.
Capital Expenditure
Total assets were recorded at INR 1,178.8 Cr in FY21. Capital employed in the Vaccine segment was INR 870.9 Cr and INR 383.6 Cr in the Formulations segment as of September 2025.
Credit Rating & Borrowing
The company carries a CARE D (Single D) rating for bank facilities totaling INR 1,021.52 Cr. This rating reflects ongoing delays in servicing debt obligations due to a strained liquidity position.
Operational Drivers
Capacity Expansion
The company operates a pharmaceutical formulations facility at Baddi, Himachal Pradesh, and a vaccine/R&D center and herbal extraction facility at Lalru, Punjab. Specific MTPA or unit capacity figures were not disclosed.
Strategic Growth
Expected Growth Rate
15%
Growth Strategy
The company plans to launch 10-12 new products in the domestic market over the next 1-3 years. It aims to sustain leadership in the transplantation segment and regain market leadership in diabetology. Growth is also targeted through the 'Nurture & Grow' strategy for domestic formulations and expanding the reach of approved products in ICH and RoW markets.
Products & Services
Vaccines (including pediatric and adult), pharmaceutical formulations for transplantation and diabetology, and nutrition products including baby care items.
Brand Portfolio
Panacea Biotec, Panacea Biotec Pharma Limited (PBPL).
New Products/Services
Planned launch of 10-12 new products in the domestic market within 1-3 years to drive future revenue contribution.
Market Expansion
Targeting ICH (International Council for Harmonization) and Rest of World (RoW) markets for pharmaceutical formulations in a phased manner.
Market Share & Ranking
The company claims a leadership position in the Indian transplantation segment and is a leading research-based biotechnology company.
Strategic Alliances
The company transferred its pharma business to its 100% subsidiary, Panacea Biotec Pharma Limited (PBPL), to streamline operations and facilitate potential strategic investments.
External Factors
Industry Trends
The industry is shifting toward advanced biotechnology and specialized vaccines. Panacea is positioning itself by leveraging its established brand equity in vaccines and focusing on chronic therapeutic areas like diabetology which are growing in India.
Competitive Landscape
Competes with major Indian and global biotech and pharma firms in the vaccine and chronic therapy segments.
Competitive Moat
The moat is built on established brand equity in vaccines and proven technology development experience. This is sustainable due to high entry barriers in vaccine manufacturing, though it is currently threatened by liquidity constraints.
Macro Economic Sensitivity
Highly sensitive to healthcare spending and government vaccine procurement policies. The baby care market growth in India is a key macro driver for the nutrition business.
Consumer Behavior
Increasing demand for specialized baby care and nutrition products in India is driving a 25% growth in the consolidated nutrition business.
Geopolitical Risks
Exposure to international regulatory standards (ICH) and trade barriers in RoW markets could impact the 11% growth rate currently seen in exports.
Regulatory & Governance
Industry Regulations
Operations are subject to stringent manufacturing standards and approvals from the International Council for Harmonization (ICH) for regulated markets.
Legal Contingencies
The company is involved in debt recovery proceedings, evidenced by a summons from the State Bank of India under the RBD Act, 1993, related to its significant outstanding debt of over INR 1,000 Cr.
Risk Analysis
Key Uncertainties
The primary uncertainty is the company's ability to restructure or service its INR 1,021.52 Cr debt, which is currently in default (CARE D). Failure to resolve this could lead to asset liquidation or operational halts.
Geographic Concentration Risk
74% of pharmaceutical revenue is concentrated in international export markets, making the company vulnerable to global trade and regulatory shifts.
Third Party Dependencies
Increased reliance on contract manufacturing for domestic revenue growth (which grew 92% YoY) introduces dependency on third-party production schedules.
Technology Obsolescence Risk
The biotechnology sector faces high risks of tech obsolescence; the company mitigates this through its dedicated R&D center and focus on new product launches.
Credit & Counterparty Risk
The company recorded an allowance for expected credit loss and doubtful advances of INR 4.15 Cr in H1 FY26, indicating some pressure on receivable quality.